&nbsp;

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

isatuximab (Compassionate),

bortezomib,

dexamethasone,

lenalidomide (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

BORTDEXA+BELA; BELA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

belantamab mafodotin (Compassionate),

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

MFOLFOX6+ZOLB

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Guidelines and Advice

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Status: Current
ID: GL 1-14
Version: 3

Oct 2019

Guidelines and Advice

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

Status: Current
ID: GL 1-23-A

Jul 2021

Regimen

MIRV

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Drugs Used:

mirvetuximab soravtansine (Compassionate)

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

MTRX(5D)

Cancer Type:

Gynecologic,

Gestational Trophoblastic Disease

Intent: Curative

Drugs Used:

methotrexate

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

MFOLFOX6+ENCO+CETU

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

cetuximab (Unfunded),

oxaliplatin,

leucovorin,

fluorouracil,

encorafenib (Unfunded)